The Drug Shortage Backup Plan
As long as Americans need prescription medication, there is a risk of drug shortages occurring. At least 50% of Americans rely on a consistent supply of medication to manage health and wellness. At the same time, there are hundreds of shortages that occur yearly, affecting everything from cancer treatments to diabetes medication, and even antibiotics. When a drug shortage occurs, the pharmacies that mass-produce the approved medication cannot create enough doses in time to help patients. Common reasons include supply chain challenges, lack of access to raw materials, or extremely high demand. When commercially manufactured drugs become unavailable, compounding pharmacies step in to fill critical gaps. There is a distinction between 503A and 503B compound pharmacies and how these facilities can help. Understanding the differences can help patients, healthcare providers, and compounding pharmacies navigate shortages efficiently.
Compounding, 503A, and 503B
Compounding is the process of creating custom medications to meet the individual needs of patients. In the past, all medications were custom-made for patients, using compounding. Today, almost all medicines are produced and distributed by large pharmaceutical corporations, which has many benefits and advantages. Compounding uses extensive training and experience to combine raw ingredients to recreate a specific drug. Some facilities combine multiple medications into a single-use form. Compound pharmacies are categorized into 2 frameworks, especially when dealing with drug shortages. A 503A pharmacy is a traditional compounding pharmacy that creates customized medications for individual patients based on specific prescriptions. A 503B facility, called an outsourcing facility, functions more like a small-scale manufacturer and can produce larger batches of medications.
Can 503A help with drug shortages?
Patients often count on standard 503A compounding pharmacies during drug shortages. The compounding pharmacist can create a customized version of an unavailable medication. The doctor will write a prescription specific to the drug shortage for a compounded version. The 503A facility receives the prescription and prepares the solution specifically for that individual. This is more of a case-by-case process, ideal for rare drugs that are difficult to source. The 503A facility has the flexibility to change the form, dose, and application method based on the doctor’s recommendations. This creates a unique treatment that benefits the patient and improves medication adherence. At the same time, there are significant limitations due to shortages that impact thousands of people. A 503A facility cannot compound multiple copies of a commercially available drug. Each patient must present a prescription. During genuine shortages, however, like the recent glucagon-like peptide-1 (GLP-1) shortage, this restriction may be temporarily lifted, allowing copies of compounded solutions.
503B and drug shortages
Compounding pharmacies with 503B authorization are vital during drug shortages. These larger facilities have access to raw materials and supply chains to create larger batches of medications. Some 503B pharmacies can create thousands of doses of a particular medicine, sometimes in advance, to help create a buffer for shortages. Hospitals and healthcare systems, in particular, rely on 503B facilities to supply compounded versions of critical medications when manufacturers struggle to meet demand. These facilities experience rigorous testing and follow the same current good manufacturing practices (cGMP) as larger manufacturers. 503B pharmacies can scale up or down and distribute to patients or healthcare facilities accordingly. As there is no need for individual prescriptions, these facilities are essential for helping with supply chain disruptions. Although there is flexibility for 503A and 503B pharmacies, there is still strong oversight by the Food and Drug Administration (FDA) to ensure quality and safety.
Considerations of compounding during shortages
Although 503A and 503B can step in to help with shortages, there are some limitations. There is an understanding that compounded medications may not undergo the same rigorous testing as manufactured drugs, especially in 503A facilities. The 503B facilities, however, follow stricter quality control guidelines with regular testing for potency. The cost of compounded medication is generally higher due to smaller production scales and labor costs There can be limitations to insurance coverage for 503A and 503B facilities. Patients receiving compounded medications from 503A pharmacies may face significant out-of-pocket expenses. Those with compounded solutions from 503B may see increased costs from healthcare facilities. With these challenges in mind, patients can find the best options for long-term health. Facilities must also decide the best options for compounding to reduce cost, serve patients, and achieve profitability.
Make the right choice
Both 503A and 503B facilities play a vital role in drug shortages. These facilities can step in to create a custom solution when standard or brand-name options are unavailable. Compounding uses the same principles and similar ingredients, allowing patients to receive treatment. Individuals dealing with temporary shortages can rely on 503A facilities. State or nationwide shortages often turn to 503B facilities, which have the authorization and resources for large-scale production. Pharmacies hoping to add value to healthcare with compounding must decide which option is best. There can be long-term benefits that serve everyone when critical drugs become unavailable.
